NOVEL ENTEROVIRUS 71 MUTATIONS ASSOCIATED WITH DISEASE SEVERITY

    公开(公告)号:US20240043944A1

    公开(公告)日:2024-02-08

    申请号:US18268842

    申请日:2021-12-20

    CPC classification number: C12Q1/701 C12Q2600/156

    Abstract: A method of detecting severe disease-associated mutations in an enterovirus 71 (EV-A71), comprising: performing an assay on a test sample containing an EV-A71 genomic RNA, a fragment thereof or an amplicon thereof, or an EV-A71 VP1 protein or fragment thereof to detect one or more severe disease-associated mutations in the EV-A71 genomic RNA, the fragment thereof or the amplicon thereof, or the EV-A71 protein or fragment thereof, wherein the one or more mutations are selected from mutations at positions corresponding to 5′ UTR nucleotide positions C580, A707, and C709 in an EV-A71 5′ UTR nucleic acid sequence and at residues corresponding to A280 and E145 in an EV-A71 VP1 protein sequence.

    RE-FOLDED HUMAN SERUM ALBUMIN AND USE THEREOF FOR ANTI-TUMOR

    公开(公告)号:US20230348566A1

    公开(公告)日:2023-11-02

    申请号:US18025637

    申请日:2021-09-10

    CPC classification number: C07K14/765 A61P35/00

    Abstract: Re-folded human serum albumin (rfHSA) and use thereof for anti-tumor are disclosed. The rfHSA comprises the primary amino acid sequence of naive human serum albumin, in which the rfHSA in a solution is oval shape, not fibrillar, and the naive HSA is globular. The rfHSA is used for treating cancer or a tumor in a subject in need thereof The rfHSA may also be used as a reagent for detecting the presence of a cancer cell associated with integrin β1 or serine/threonine protein kinase Akt and extracellular signal-regulated kinase 1/2 (ERK1/2) in a tumor sample or as a reagent for inhibiting phosphorylation of Akt and ERK 1/2 in a cancer cell sample. A cell lysate of a cancer cell treated with rfHSA, a vaccine composition comprising the cancer cell lysate, and use thereof are also disclosed. Also disclosed is a method tor preparing rfHSA.

Patent Agency Ranking